Hybrid films loaded with 5-fluorouracil and Reglan for synergistic treatment of colon cancer via asynchronous dual-drug delivery

Hybrid films loaded with 5-fluorouracil and Reglan for synergistic treatment of colon cancer via asynchronous dual-drug delivery

13 June 2024 | Hairong Mao, Jianfeng Zhou, Liang Yan, Shuping Zhang, Deng-Guang Yu
This study presents a novel approach to synergistically treat colon cancer using hybrid films loaded with 5-fluorouracil (5-FU) and Reglan (ondansetron). The hybrid films are designed to achieve asynchronous dual-drug delivery, where Reglan is rapidly released first to prevent vomiting, followed by sustained release of 5-FU. The drugs are loaded into core-shell nanoparticles via coaxial electrospraying, which are then incorporated into polyvinylpyrrolidone K30 (PVP K30) films through casting. The core-shell nanoparticles consist of 5-FU and cellulose acetate (CA), with the CA shell preventing initial drug release. The hybrid films exhibit a semitransparent appearance and a thickness of approximately 2.0 mm. In vitro dissolution tests show that Reglan is rapidly released, while 5-FU is released in a sustained manner over 30 hours. The study demonstrates the potential of this hybrid film for synergistic cancer therapy, combining the advantages of advanced nanotechniques and traditional pharmaceutical techniques.This study presents a novel approach to synergistically treat colon cancer using hybrid films loaded with 5-fluorouracil (5-FU) and Reglan (ondansetron). The hybrid films are designed to achieve asynchronous dual-drug delivery, where Reglan is rapidly released first to prevent vomiting, followed by sustained release of 5-FU. The drugs are loaded into core-shell nanoparticles via coaxial electrospraying, which are then incorporated into polyvinylpyrrolidone K30 (PVP K30) films through casting. The core-shell nanoparticles consist of 5-FU and cellulose acetate (CA), with the CA shell preventing initial drug release. The hybrid films exhibit a semitransparent appearance and a thickness of approximately 2.0 mm. In vitro dissolution tests show that Reglan is rapidly released, while 5-FU is released in a sustained manner over 30 hours. The study demonstrates the potential of this hybrid film for synergistic cancer therapy, combining the advantages of advanced nanotechniques and traditional pharmaceutical techniques.
Reach us at info@study.space